公开(公告)号：DE602005021821D1

公开(公告)日：2010-07-22

申请号：DE602005021821

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  YUAN HSIANG-YU ,  CHEN JIN-JER

IPC: C12Q1/68

公开(公告)号：AU2007249225A1

公开(公告)日：2007-11-22

申请号：AU2007249225

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  LIN HSIN-YU ,  CHEN WEI-HSUAN ,  CHANG CHI-FENG ,  SHEN CHIH-LUNG

IPC: C12Q1/68

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：BRPI0416355A

公开(公告)日：2007-03-13

申请号：BRPI0416355

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  CHUNG WEN-HUNG ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

公开(公告)号：CA2544369A1

公开(公告)日：2005-05-26

申请号：CA2544369

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： WU JER-YUARN ,  CHUNG WEN-HUNG ,  HUNG SHUEN-IU ,  CHEN YUAN-TSONG

IPC: C12Q1/68 ,  G01N33/94

Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug hypersensitivity syndrome (HSS). It was discovered that an HLA-13 allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA - B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all t he patients tested have the HLA-13*1502 allele. In addition, another HLA-13 allele, HLA-B*5801, is particularly associated with SJS/TEN or HSS induced b y allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythem a multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-13*4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphis m markers) located between the DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

公开(公告)号：CY1110760T1

公开(公告)日：2015-06-10

申请号：CY101100782

申请日：2010-08-25

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  CHUNG WEN-HUNG ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

Abstract: Ηπαρούσαεφεύρεσηπαρέχειμιαμέθοδοπρόβλεψηςτουκινδύνουπουαντιμετωπίζειέναςασθενήςνααναπτύξειανεπιθύμητεςαντιδράσειςαπότηχρήσηφαρμάκων, ιδίωςτοσύνδρομο Stevens-Johnson (SJS), τηντοξικήεπιδερμικήνεκρόλυση (TEN), ήτοσύνδρομουπερευαισθησίαςσεκάποιοφάρμακο (HSS). Ανακαλύφθηκεότιένααλληλόμορφοτου HLA-13, το HLA-B*1502, σχετίζεταιμετα SJS/TEN πουεπάγονταιαπόμιαποικιλίαφαρμάκων. Ησυσχέτισημετο HLA-B*1502 είναιπιοσημαντικήγιατααπότηνκαρβαμαζεπίνηεπαγόμενα SJS/TEN, όπουόλοιοιασθενείςπουελέγχθηκανείχαντο HLA-13*1502 αλληλόμορφο. Επιπλέον, έναάλλοαλληλόμορφοτου HLA-13, το HLA-B*5801, σχετίζεταιιδιαίτεραμετα SJS/TEN ή HSS πουπροκαλούνταιαπότηναλλοπουρινόλη. Ηπιότερεςδερματικέςαντιδράσεις, όπωςκηλιδοβλατιδώδεςεξάνθημα, πολύμορφοερύθημα (ΕΜ), κνίδωση, καισταθερόφαρμακευτικόεξάνθημα, είναιιδιαίτερασυνδεδεμένεςμεένατρίτοαλληλόμορφοτο HLA-13*4601. Γιαοποιοδήποτεαπότααλληλόμορφα, μπορούνεπίσηςναχρησιμοποιηθούνγιατηδοκιμήγενετικοίδείκτες (π.χ. HLA δείκτες, μικροδορυφορικοίδείκτεςή δείκτεςπολυμορφισμούενόςνουκλεοτιδίουπουβρίσκονταιστηνμεταξύ DRBI και HLA Απεριοχήτουειδικούαπλότυπου HLA-B.

公开(公告)号：CA2591840C

公开(公告)日：2012-07-10

申请号：CA2591840

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  YUAN HSIANG-YU ,  CHEN JIN-JER

IPC: C12Q1/68

Abstract: We discovered that a polymorphism in the promoter of the VKORCI gene is associated with warfarin sensitivity. This polymorphism can explain both the inter~individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORCI gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.

公开(公告)号：PL1831402T3

公开(公告)日：2010-12-31

申请号：PL05855433

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  YUAN HSIANG-YU ,  CHEN JIN-JER

IPC: C12Q1/68

公开(公告)号：ES2347167T3

公开(公告)日：2010-10-26

申请号：ES05855433

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  YUAN HSIANG-YU ,  CHEN JIN-JER

IPC: C12Q1/68

Abstract: Un procedimiento de predecir un intervalo de dosis de una warfarina para un paciente humano, que comprende: investigar el nucleótido en la posición 3673 de la SEQ ID N.º:1 del paciente; determinar si el paciente es sensible a warfarina o si es resistente a warfarina en base al nucleótido en la posición 3673; en la que homocigosis AA, heterocigosis AG, y homocigosis GG en la posición 3673 indican que el paciente es sensible a warfarina, que es sensible de forma intermedia a warfarina y que es resistente a warfarina, respectivamente; y predecir un intervalo de dosificación de warfarina en base a la sensibilidad o resistencia a warfarina del paciente.

公开(公告)号：DK1831402T3

公开(公告)日：2010-09-20

申请号：DK05855433

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： YUAN HSIANG-YU ,  CHEN JIN-JER ,  CHEN YUAN-TSONG

IPC: C12Q1/68

公开(公告)号：AU2004289951B2

公开(公告)日：2009-10-22

申请号：AU2004289951

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： CHUNG WEN-HUNG ,  CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.